EP1385875A2 - Epitopes du virus de l'hepatite c specifiques des lymphocytes t cd4+ - Google Patents

Epitopes du virus de l'hepatite c specifiques des lymphocytes t cd4+

Info

Publication number
EP1385875A2
EP1385875A2 EP01985703A EP01985703A EP1385875A2 EP 1385875 A2 EP1385875 A2 EP 1385875A2 EP 01985703 A EP01985703 A EP 01985703A EP 01985703 A EP01985703 A EP 01985703A EP 1385875 A2 EP1385875 A2 EP 1385875A2
Authority
EP
European Patent Office
Prior art keywords
epitopes
hcv
lymphocytes
vaccine
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01985703A
Other languages
German (de)
English (en)
Inventor
Jörn Tilman GERLACH
Helmut Diepolder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immusystems GmbH
Original Assignee
Immusystems GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immusystems GmbH filed Critical Immusystems GmbH
Priority to EP01985703A priority Critical patent/EP1385875A2/fr
Publication of EP1385875A2 publication Critical patent/EP1385875A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the invention relates to hepatitis C virus epitopes which are specific for CD4 + T lymphocytes and to vaccines which contain these epitopes.
  • the hepatitis C virus hereinafter referred to as HCV, was identified in 1989 and is an RNA virus from the Flaviviridae family. It consists of an RNA single strand of approximately 9400 nucleotides that encode a precursor polyprotein of approximately 3000 amino acids. This polyprotein is translated in an open reading frame and proteolytically cleaved post-translationally.
  • the virus is highly variable, and there are various virus isolates known as genotypes, whose geographical distribution is very different. Today, more than six genotypes are differentiated worldwide. These genotypes are subdivided into subtypes. The genetic variability is inter-individual and intra-individual (within an infected individual). The intra-individual subtypes are the so-called HCV quasi-species, but they are related to different virus sequences that result from inaccurate replication.
  • hepatitis C is one of the most important chronic viral infections. At least 180 million infected individuals are currently expected. According to calculations by the Center of Disease Control in the USA, there will also be an increase in hepatitis C-associated diseases by 2010 due to the long latency period after infection with HCV.
  • the HCV is predominantly transmitted parenterally and was the main cause of post-transfusion hepatitis NonA-NonB until it was discovered.
  • Routine testing of all blood products with 2nd and 3rd generation HCV antibody tests has dramatically reduced the number of post-transfusion hepatitis.
  • the so-called sporadic hepatitis C and IV drug abuse are now considered the main transmission pathways for new HCV infections. No measures are currently known to effectively prevent new infections in this way.
  • HCV causes chronic inflammation of the liver (hepatitis), which over the course of many years can lead to further complications, such as cirrhosis of the liver.
  • cirrhosis of the liver As part of cirrhosis of the liver that has existed for years, about 5% of all infected people develop hepatocellular carcinoma. In the western world, hepatitis C therefore ranks first as the cause of a liver transplant. The health care costs of these transplants are significant.
  • T-lymphocytes are isolated from peripheral blood and the HCV-specific CD4 + T-lymphocytes contained therein are enriched by repeated stimulation with the corresponding virus protein in vitro to produce so-called specific T cell lines.
  • specific T cell lines By analyzing the growth behavior (incorporation of radioactively labeled nucleotides) of these specific T cell lines after stimulation with HCV protein and / or the smaller subunits, the peptides, the sequence of the T cell epitope can be narrowed.
  • the analysis of T cell lines, in comparison to T cell clones gives inaccurate results due to the cell mixture with regard to the sequence specifically recognized by the CD4 + T lymphocytes.
  • HCV epitopes which are specific to CD4 + T lymphocytes and which contain the sequence:
  • HCV epitopes which are specific to CD4 + T lymphocytes and contain the sequence:
  • Another solution is a vaccine which contains at least one of the epitopes 1) to 21) according to the invention.
  • the vaccine preferably contains the epitope with the layer eel 773-1783, namely 3) QYLAGLSTLPG.
  • the vaccine can particularly preferably contain a mixture of the epitopes 1) to 21) according to the invention.
  • other HCV epitopes may also be present.
  • Figure 1 shows the epitope mapping of the epitope at position aa1765-1784.
  • Fig. 6 mapping the epitope at position aa1585-1594 using N- or C-terminally truncated peptides.
  • the epitopes according to the invention are specifically recognized by CD4 + T lymphocytes which are formed in the patient in the case of a self-limited HCV infection.
  • the position of the epitopes according to the invention on the HCV protein is in each case for 1) aa1585-1594, 2) aa1655-1675, 3) aa1773-1783, 4) aa1787-1795, 5) aa1809-1817 and 6) aa1207-1226.7 ) aa1580 - 1599, 8) eel 654 - 1673, 9) eel 768 - 1788, 10) eel 782 - 1800, 11) eel 804 - 1822, 12) aa1535 - 1554, 13) aa1875 - 1894, 14) aa1406 - 1434 , 15) aa1689 - 1708, 16) aa1327 - 1341, 17) 1337 - 1352, 18) aa1457 - 1472, 19) aa1507 - 1522, 20) aa2581 - 2595 and 21) aa
  • the epitopes according to the invention are preferably the sequences 1) to 21) themselves.
  • the epitopes according to the invention are selected from the group consisting of 1) YLVAYQATVC, 2) WTSTWVLVGGVLAALAAYCL, 3) QYLAGLSTLPG, 4) IASLMAFTA, 5) FNILGGWVA, 6) SPVFTDNSSPPAVPQSFQVA, 7) GENLPYLVAYQATVCARAQA, 8) EWTSTWVLVGGVLAALAA, 9) FISGIQYLAGLSTLPGNPAIA, 10) PGNPAIASLMAFTAAVTSP, 11) SQTLLFNILGGWVAAQLAA, 12) TSVRLRAYLNTPGLPVCQDH, 13) STEDLVNLLPAILSPGALW, 14) KLVALGINAVAYYRGLDVSVIPTSGDVW, 15) SGKPAIIPDREVLYREFDEM,
  • the derivatives according to the invention of epitopes 1) to 21) with comparable specificity can be found in the same way as these epitopes using the HCV-specific T cell clones by means of N- and C-terminal truncated peptides or by exchanging single or several amino acids in the sequences 1) to 21) and checking the specificity of these changed sequences.
  • the epitopes according to the invention are highly immunogenic, highly conserved and in the immediate vicinity of known HCV epitopes which are specific to CD8 + T lymphocytes.
  • HCV epitopes specific to CD4 + T lymphocytes they can mediate so-called T cell help for cytotoxic CD8 + T lymphocytes in addition to induction of CD4 + T lymphocytes. These CD8 + T lymphocytes are activated by the cytokines of stimulated CD4 + T lymphocytes. In this context, the immediate proximity of the HCV epitopes found here to known CD8 + epitopes is particularly important.
  • Epitopes 1) to 16) were recognized by fresh peripheral mononuclear cells (PBMC) from 18 patients with acute HCV, namely for 1) of 6 patients, for 2) of 4 patients, for 3) of 6 patients, for 4) of 3 Patients for 5) of 4 patients, for 7) from one patient, for 8) from two different clones of a patient, and for 9) and 10) from one patient.
  • Epitopes 11) to 16) were determined with the help of HCV-specific T cell clones from patients after liver transplantation, in whom virus elimination had taken place after the transplantation despite immunosuppression.
  • the epitopes according to the invention not only stimulated the T lymphocytes of the patients from whom the T cell clones originate, but also the fresh peripheral mononuclear cells (PBMC) from different patients with acute hepatitis C and a self-limited course.
  • PBMC peripheral mononuclear cells
  • a protective T cell vaccination they are therefore ideally suited for vaccinating healthy people or hepatitis C patients with different HLA characteristics.
  • the epitopes according to the invention can be used alone or with one or more auxiliary substances as medicaments, preferably as vaccines.
  • the vaccine according to the invention contains at least one epitope according to the invention, preferably a mixture of epitopes according to the invention, in particular the epitope at position aa1773-1783, to which further epitopes or epitopes according to the invention can optionally be added at other positions.
  • the excipients are preferably selected from the group consisting of fowl pox virus, modified vaccinia virus Ankara, virosomes, TransVax ® and other immune response enhancing substances.
  • the vaccine according to the invention can be administered orally, parenterally, intramuscularly, intravenously, subcutaneously or intracutaneously.
  • the epitopes according to the invention are epitopes that can be used as a T cell stimulating vaccine.
  • a vaccine which contains the epitopes according to the invention, has a vaccination with the entire virus protein, which contains various epitopes for virus-specific T-lymphocytes and only B-lymphocytes and
  • CD4 + T lymphocytes induce the advantage that it selectively induces specific T lymphocytes, CD4 + and / or CD8 + T lymphocytes.
  • the epitopes according to the invention additionally have a higher immunogenicity compared to the entire virus protein, as a result of which a better vaccination result is achieved.
  • the vaccine according to the invention thus enables the induction of an immune response in healthy people and therefore serves as a prophylactic vaccination.
  • the vaccine according to the invention can also induce an immune response in chronically HCV-infected people and thus serve as a therapeutic vaccine.
  • the coding c-DNA of these epitopes can be used in a DNA vaccine, a special vaccination method.
  • the DNA coding for the corresponding epitopes is cloned into a vector. This construct is in turn administered parenterally to the individual to be vaccinated (eg Immunology and Cell Biology, Volume 75, pages 382 to 388).
  • different DNA sequences can encode one of the epitopes according to the invention (see Current protocols, Wiley).
  • the epitopes according to the invention can also be used in the diagnosis of the course of an HCV infection by monitoring the amount of CD4 + T lymphocytes which specifically recognize the epitope in question in the blood of the patient with a hepatitis C infection. This can be carried out, for example, using a diagnostic kit which comprises one or more of the epitopes according to the invention.
  • Heparinized blood was drawn from patients with a self-limited course of acute hepatitis C in the first 6 months after the onset of the disease.
  • the fresh peripheral mononuclear blood cells (PBMC) were isolated by density gradient centrifugation on Ficoll gradients and suspended in a culture medium (RPMI1640, Gibco). 50 ⁇ l of this cell suspension (concentration of 1x10 6 cells per ml) was placed on sterile 96-well culture plates. Ten samples of this cell mixture were stimulated by adding a recombinant HCV protein. The final concentration of the protein was 1 ⁇ g / ml.
  • the cell culture plates were cultivated for 5 days at 37 ° C. and 5% CO 2 . On day 6, culture IL-2 was added.
  • the final concentration of IL-2 was 15U / ml and the cells were cultivated for a further three days at 37 ° C. and 5% CO 2 . Those holes in the culture plate that appeared to be strongly stimulated under microscopic control on day ten were collected and distributed to a further culture plate in serial dilution stages. A hole was selected microscopically, which contained approximately 150 cells. These 150 cells were diluted with medium and spread over 300 holes so that statistically half a cell was contained in each hole. IL-2 was then added to a final concentration of 15U / ml. In addition, 3x10 4 autologous and 3000 Rad irradiated PBMC and phythema agglutinin (PHA) were added to each hole as growth factor.
  • PHA phythema agglutinin
  • the clones were expanded and then expanded into one Proliferation assay with HCV proteins tested for antigen specificity.
  • the antigen specificity was first determined by stimulation with proteins and then, in the case of a positive result, with 20 amino acid long peptides (20mer peptides), as shown in FIG. 1.
  • T cell clones were stimulated with proteins, as shown in FIG. 1 on the left, and antigen-presenting cells, and the stimulation was measured as incorporation of radioactively labeled 3 H, as shown in FIG. 1 on the right.
  • stimulation was carried out with 20 mer peptides corresponding to the protein sequence, each overlapping by 10 amino acids, and the incorporation of 3 H was measured again. The corresponding epitope was reduced to 20 amino acids.
  • the epitope the smallest still stimulating sequence within the 20mer peptide, was analyzed with truncated peptides, i.e. the original 20mer peptide was truncated in the ascending order from the N-terminal as shown in Figure 2.
  • the same procedure was used with peptides truncated from the C-terminal.
  • a proliferation assay showed the amino acid to which the peptide could be truncated without having to accept any significant loss of stimulation.
  • the epitope QYLAGLSTLPG is obtained, as shown in FIG. 2.
  • a high degree of conservation of the epitopes was found despite the known high genetic variability of the HCV.
  • Cell receptor can be subject to minor fluctuations in individual cases or can be fermented by loss of a single amino acid, as well the synthesis length of the peptides can be subject to fluctuations, the epitopes 1 to 5, when used in a vaccine, should each carry five amino acids N-terminal and C-terminal as protection against degradation or to optimize the synthesis and ensure the antigen presentation, these extended epitopes for example, epitopes 7 through 11 can be.
  • Clones were obtained according to the procedure of Example 1. The antigen specificity of these clones was then determined as shown in Figure 3. The corresponding epitope with 20 amino acids is obtained. The epitope within this 20mer peptide was then determined as shown in Figure 4. The epitope IASLMAFTA is obtained.
  • Clones were obtained according to the procedure of Example 1. The antigen specificity of these clones was then determined as shown in Figure 5. The corresponding epitope with 20 amino acids, namely WTSTWVLVGGVLAALAAYCL, is obtained according to Example 1.
  • Example 5 Clones were obtained according to the procedure of Example 1. The antigen specificity was also determined as described in Example 1 and the corresponding epitope with 20 amino acids was obtained. Then, as shown in Figure 6, the epitope was determined, namely YLVAYQATVC.
  • Example 5 The antigen specificity was also determined as described in Example 1 and the corresponding epitope with 20 amino acids was obtained. Then, as shown in Figure 6, the epitope was determined, namely YLVAYQATVC.
  • Example 5 Example 5
  • Example 2 Following the procedure of Example 1, clones from patients after liver transplantation were made from routinely drawn blood. In patients after liver transplantation, the specificity of the T cell clones was analyzed using the ELISPOT assay.
  • a detection antibody in this case against interferon gamma, is attached to a nitrocellulose-coated microtiter plate and adheres to the nitrocellulose.
  • the specific T cell clones are added together with antigen presenting cells and the antigen to be tested.
  • the clonal T lymphocytes secrete Interferon gamma.
  • This cytokine is "captured" by the detection antibodies over 48 hours.
  • a second specific antibody is added which recognizes and labels the fixed cytokine-antibody complex. The second antibody can then be visualized by a dye reaction so that the antigen-specific impress secreted cytokines as spots, which can finally be counted under the microscope and represent a measure of the antigen specificity in relation to the control.
  • epitopes can also be mapped with the ELISPOT assay.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Epitopes du virus de l'hépatite C qui sont spécifiques des lymphocytes T CD4+, ainsi que vaccins qui contiennent ces épitopes.
EP01985703A 2000-09-28 2001-09-28 Epitopes du virus de l'hepatite c specifiques des lymphocytes t cd4+ Withdrawn EP1385875A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP01985703A EP1385875A2 (fr) 2000-09-28 2001-09-28 Epitopes du virus de l'hepatite c specifiques des lymphocytes t cd4+

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP00121138A EP1195381A1 (fr) 2000-09-28 2000-09-28 Epitopes du virus de l'hépatite C spécifiques à des lymphocytes T de type CD4+
EP00121138 2000-09-28
PCT/EP2001/011263 WO2002026785A2 (fr) 2000-09-28 2001-09-28 Epitopes du virus de l'hepatite c specifiques des lymphocytes t cd4?+¿
EP01985703A EP1385875A2 (fr) 2000-09-28 2001-09-28 Epitopes du virus de l'hepatite c specifiques des lymphocytes t cd4+

Publications (1)

Publication Number Publication Date
EP1385875A2 true EP1385875A2 (fr) 2004-02-04

Family

ID=8169969

Family Applications (2)

Application Number Title Priority Date Filing Date
EP00121138A Withdrawn EP1195381A1 (fr) 2000-09-28 2000-09-28 Epitopes du virus de l'hépatite C spécifiques à des lymphocytes T de type CD4+
EP01985703A Withdrawn EP1385875A2 (fr) 2000-09-28 2001-09-28 Epitopes du virus de l'hepatite c specifiques des lymphocytes t cd4+

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP00121138A Withdrawn EP1195381A1 (fr) 2000-09-28 2000-09-28 Epitopes du virus de l'hépatite C spécifiques à des lymphocytes T de type CD4+

Country Status (4)

Country Link
US (2) US7108856B2 (fr)
EP (2) EP1195381A1 (fr)
AU (1) AU2002223569A1 (fr)
WO (1) WO2002026785A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT408721B (de) * 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
EP1357127A1 (fr) 2002-04-10 2003-10-29 Immusystems GmbH Epitopes du virus de l'hépatite C spécifiques à des lymphocytes T de type CD4+
JP4342519B2 (ja) * 2003-09-22 2009-10-14 株式会社グリーンペプタイド Ｃ型肝炎ウイルス由来ペプチド
EP2646459B1 (fr) 2010-12-02 2020-01-08 Bionor Immuno AS Conception d'échafaudage peptidique
AU2012204955B2 (en) 2011-01-06 2016-10-06 Bionor Immuno As Monomeric and multimeric immunogenic peptides
IN2014KN02769A (fr) 2012-06-06 2015-05-08 Bionor Immuno As

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0696640A2 (fr) * 1994-08-12 1996-02-14 Boehringer Mannheim Gmbh Antigènes de recombinaison venant de la région NS3 du virus de l'hépatite C
WO2001024822A2 (fr) * 1999-10-01 2001-04-12 Cistem Biotechnologies Gmbh Composition pharmaceutique comprenant un antigene

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3316976A1 (de) * 1983-05-09 1984-11-15 Siemens AG, 1000 Berlin und 8000 München Elektronischer installationsschalter
RU2148587C1 (ru) * 1991-06-24 2000-05-10 Чирон Корпорейшн Полипептид и способ его получения, реагент для иммуноанализа, способ определения присутствия антител и способ индукции иммунного ответа
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
DE69230917T3 (de) * 1991-09-16 2005-04-07 Abbott Laboratories, Abbott Park Verfahren zur detektion von hepatitis c
AU6653394A (en) * 1992-12-07 1994-07-04 Akzo Nobel N.V. Hepatitis c virus (hcv) non-structural-3 peptides, antibodies thereto and methods for the detection of hcv
DE69435292D1 (de) * 1993-03-05 2010-06-17 Epimmune Inc Verfahren zur herstellung von immunogenen hla-a2.1-bindenden peptiden
JPH07285994A (ja) * 1994-02-28 1995-10-31 Nippon Seibutsu Kagaku Kenkyusho Ｃ型肝炎ウイルス（ｈｃｖ）感染患者血清と高い反応性を示す合成ぺプチド及びこれを用いたｈｃｖ感染の診断法
US5709995A (en) * 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
US6413517B1 (en) * 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes
EP1787654B1 (fr) * 1997-07-10 2013-09-11 Mannkind Corporation Vaccination intralymphatique pour induire des réponses CTL effecteurs prolongeé
CA2323632A1 (fr) * 1998-03-13 1999-09-16 Epimmune Inc. Peptides de liaison de hla et leurs applications
ATE518956T1 (de) * 1998-05-13 2011-08-15 Epimmune Inc Expressionsvektoren zur stimulierung einer immunantwort und verfahren zu deren verwendung
US20040091995A1 (en) * 2001-06-15 2004-05-13 Jeffrey Schlom Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0696640A2 (fr) * 1994-08-12 1996-02-14 Boehringer Mannheim Gmbh Antigènes de recombinaison venant de la région NS3 du virus de l'hépatite C
WO2001024822A2 (fr) * 1999-10-01 2001-04-12 Cistem Biotechnologies Gmbh Composition pharmaceutique comprenant un antigene

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
V. LAMONACA ET AL.: "Conserved Hepatitis C Virus Sequences are highly immunogenic for CD4+ Cells: Implications for Vaccine Development", HEPATOLOGY, vol. 30, no. 4, October 1999 (1999-10-01), pages 1088 - 1098, XP002188421 *

Also Published As

Publication number Publication date
US7108856B2 (en) 2006-09-19
US20070048333A1 (en) 2007-03-01
WO2002026785A2 (fr) 2002-04-04
US20030186224A1 (en) 2003-10-02
EP1195381A1 (fr) 2002-04-10
WO2002026785A3 (fr) 2003-11-06
AU2002223569A1 (en) 2002-04-08

Similar Documents

Publication Publication Date Title
Seki et al. Type II collagen-induced murine arthritis. I. Induction and perpetuation of arthritis require synergy between humoral and cell-mediated immunity.
DE69518642T3 (de) Peptide zur induktion von immunantwort durch zytotoxischen t lymphocyten gegen das virus von hepatitis c
DE3886363T3 (de) NANBV-Diagnostika
DE69433518T2 (de) Nukleinsäure, die für einen tumor abstossungsantigenvorläufer kodiert
DE69818445T2 (de) Verwendung von verbindungen die an ein zytoplasmatischen dipeptidase binden zur potenzierung des immunantworts
DE69826304T2 (de) Immunoreaktive peptid ctl epitope von menschlichem cytomegalovirus
DE69733352T2 (de) Hla-a2.1 bindende peptide und deren verwendung
DE102004026135A1 (de) An MHC-Moleküle bindende Tumor-assoziierte Peptide
Delfs et al. Coexistence of acetylcholinesterase and somatostatin-immunoreactivity in neurons cultured from rat cerebrum
WO1997019174A1 (fr) Antigenes vp du virus jc
EP0669001B1 (fr) Determination de motifs peptidiques sur des molecules du cmh
EP0584715B1 (fr) Pocédé pour l'isolation et la cultivation de cellules transformées et leur utilisation pour la préparation des anticorps contre ces cellules.
DE60114018T2 (de) Von zellen präsentierte peptide
DE112011102640T5 (de) Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung undPrävention von Infektionskrankheiten
DE69830251T2 (de) Langes pentraxin ptx3 enthaltende pharmazeutische zusammensetzungen
DE60213221T2 (de) Neuartige polynukleotide und polypeptide des ifnalpha-21 gens
GANLEY‐LEAL et al. Comparison of Schistosoma mansoni irradiated cercariae and Sm23 DNA vaccines
EP1385875A2 (fr) Epitopes du virus de l'hepatite c specifiques des lymphocytes t cd4+
DE19917195B4 (de) Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
DE60028248T2 (de) Verfahren zur Reduzierung der Immunogenität von Staphylokinase durch Entfernen von T-Zell-Epitopen
DE4423392A1 (de) Verfahren zur Identifizierung antigener Peptide
DE60319350T2 (de) Gemeinsame epitope von antigenen aus einer multigen-familie
WO2020245126A1 (fr) Peptides d'antigènes tumoraux hla de classe i et ii pour le traitement des carcinomes mammaires et/ou du sein
DE60319990T2 (de) Mischung von peptiden aus den proteinen c und ns3 des hepatitis c-virus, und deren verwendung
EP1357127A1 (fr) Epitopes du virus de l'hépatite C spécifiques à des lymphocytes T de type CD4+

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030416

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 31/14 B

Ipc: 7G 01N 33/68 B

Ipc: 7C 12N 15/51 B

Ipc: 7C 07K 14/18 A

Ipc: 7A 61K 39/29 B

17Q First examination report despatched

Effective date: 20061229

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091103